Hormesis is central to toxicology,pharmacology and risk assessment

Abstract

This paper summarizes numerous conceptual and experimental advances over the past two decades in the study of hormesis. Hormesis is now generally accepted as a real and reproducible biological phenomenon, being highly generalized and independent of biological model, endpoint measured and chemical class/physical stressor. The quantitative features of the hormetic dose response are generally highly consistent, regardless of the model and mechanism, and represent a quantitative index of biological plasticity at multiple levels of biological organization. The hormetic dose-response model has been demonstrated to make far more accurate predictions of responses in low dose zones than either the threshold or linear at low dose models. Numerous therapeutic agents widely used by humans are based on the hormetic dose response and its low dose stimulatory characteristics. It is expected that as low dose responses come to dominate toxicological research that risk assessment practices will incorporate hormetic concepts in the standard setting process.

Keywords

hormesis hormetic biphasic U-shaped adaptive response inverted U-shaped

References

Calabrese EJ The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch Toxicol 2009; 83: 203-225.

Calabrese EJ Getting the dose-response wrong: why hormesis became marginalized and the threshold model accepted. Arch Toxicol 2009; 83: 227-247.

Calabrese EJ Hormesis: why it is important to toxicology and toxicologists. Environ Toxicol Chem 2008 ; 27: 1451-1474.

Calabrese EJ Historical blunders: how toxicology got the dose-response relationship half right. Cell Mol Biol 2005; 51: 643-654.

Calabrese EJ , Baldwin LA The frequency of U-shaped dose-responses in the toxicological literature. Tox Sci 2001 ; 62: 330-338.

Calabrese EJ , Baldwin LA The hormetic dose response model is more common than the threshold model in toxicology. Tox Sci 2003; 71: 246-250.

Calabrese EJ , Staudenmayer JW , Stanek EJ , Hoffmann GR Hormesis outperforms threshold model in NCI antitumor drug screening data. Tox Sci 2006 ; 94: 368-378.

Calabrese EJ , Staudenmayer JW , Stanek EJ Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Cur Opin Drug Disc Develop 2006; 9: 117-123.

Calabrese EJ , Stanek III, EJ , Nascarella MA , Hoffmann GR Hormesis predicts low-dose responses better than threshold models. Int J Toxicol 2008; 27: 369-378.

10.

Calabrese EJ , Blain R. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol Appl Pharmacol 2005; 202: 289-301.

11.

Calabrese EJ , Blain RB Hormesis and plant biology. Environ Poll 2009 ; 157: 42-48.

12.

Bruce RD , Carlton WW , Ferber KH , Hughes DH , Quast JF , Salsburg DS , et al. Re-examination of the ED01 study why the society of toxicology became involved. Funda Appl Toxicol 1981; 1: 26-128.

13.

Calabrese EJ , Baldwin L. The dose determines the stimulation (and poison): development of a chemical hormesis database. Int J Toxicol 1997; 16: 545-559.

14.

Calabrese EJ Prostaglandins: biphasic dose responses. Crit Rev Toxicol 2001; 31: 475-488.

15.

Calabrese EJ Nitric oxide: biphasic dose responses. Crit Rev Toxicol 2001; 31: 489-502.

16.

Calabrese EJ Estrogen and related compounds: biphasic dose responses. Crit Rev Toxicol 2001; 31: 503-516.

17.

Calabrese EJ Androgens: biphasic dose responses. Crit Rev Toxicol 2001; 31: 517-522.

18.

Calabrese EJ Adrenergic receptors: biphasic dose responses . Crit Rev Toxicol 2001; 31: 523-538.

19.

Calabrese EJ Adenosine: biphasic dose responses. Crit Rev Toxicol 2001; 31: 539-552.

20.

Calabrese EJ 5-Hydroxytryptamine (serotonin): biphasic dose responses. Crit Rev Toxicol 2001; 31: 553-562.

21.

Calabrese EJ Dopamine: biphasic dose responses. Crit Rev Toxicol 2001; 31: 563-584.

22.

Calabrese EJ Opiates: biphasic dose responses. Crit Rev Toxicol 2001; 31: 585-604.

23.

Calabrese EJ, Baldwin LA (guest eds.). Chemotherapeutics and hormesis . Crit Rev Toxicol 2003; 33: 305-354.

24.

Calabrese EJ, Baldwin LA (guest eds.). Ethanol and hormesis. Crit Rev Toxicol 2003; 33: 407-424.

25.

Calabrese EJ , Baldwin LA (guest eds). Inorganics and hormesis . Crit Rev Toxicol 2003; 33: 215-304.

26.

Calabrese EJ Hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implications. Crit Rev Toxicol 2005; 35: 89-296.

27.

Calabrese EJ Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 2005; 35: 463-582.

28.

Calabrese EJ Neuroscience and hormesis: overview and general findings. Crit Rev Toxicol 2008; 38: 249-252.

29.

Calabrese EJ Dose-response features of neuroprotective agents: An integrative summary. Crit Rev Toxicol 2008 ; 38: 253-248.

30.

Calabrese EJ Pharmacological enhancement of neuronal survival . Crit Rev Toxicol 2008; 38: 349-390.

31.

Calabrese EJ Enhancing and regulating neurite outgrowth . Crit Rev Toxicol 2008; 38: 391-418.

32.

Calabrese EJ Alzheimer’s disease drugs: an application of the hormetic dose-response model. Crit Rev Toxicol 2008; 38: 419-452.

33.

Calabrese EJ Stress biology and hormesis: the Yerkes-Dodson law in psychology - a special case of the hormesis dose response. Crit Rev Toxicol 2008; 38: 453-462.

34.

Calabrese EJ Astrocytes: adaptive responses to low doses of neurotoxins. Crit Rev Toxicol, 2008; 38: 463-472.

35.

Calabrese EJ P-glycoprotein efflux transporter activity often displays biphasic dose-response relationships. Crit Rev Toxicol 2008; 38: 473-487.

36.

Calabrese EJ An assessment of anxiolytic drug screening tests: hormetic dose responses predominate. Crit Rev Toxicol 2008; 38: 489-542.

37.

Calabrese EJ Modulation of the epileptic seizure threshold: implications of biphasic dose responses. Crit Rev Toxicol 2008; 38: 543-556.

38.

Calabrese EJ Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Crit Rev Toxicol 2008 ; 38: 557-577.

39.

Calabrese EJ Pain and U-shaped dose responses: occurrence, mechanisms, and clinical implications. Crit Rev Toxicol 2008; 38: 579-590.

40.

Calabrese EJ U-shaped dose response in behavioral pharmacology: historical foundations. Crit Rev Toxicol 2008 ; 38: 591-598.

41.

Calabrese EJ Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant . Crit Rev Toxicol 2008; 38: 599-618.

42.

White RH , Cote I. , Zeise L. , Fox M. , Dominici F. , Burke TA , et al. State-of-the-science workshop report: issues and approaches in low dose-response extrapolation for environmental health risk assessment . Environ Health Perspect 2009; 117: 283-287.

43.

Calabrese EJ , Baldwin LA Defining hormesis. Hum Exper Toxicol 2002; 21: 91-97.

44.

Calabrese EJ , Baldwin LA A general classification of U-shaped dose-response relationships. Hum Exp Toxicol 1998; 17: 353-364.

45.

Calabrese EJ , Howe KJ Stimulation of growth of peppermint (menthe-piperita) by phosfon, a growth retardant. Physiol Plant 1976; 37: 163-165.

46.

Stebbing ARD. A theory for growth hormesis. Mut Res-Fund Mol Mech Mut 1998; 403: 249-258.

47.

Calabrese EJ Evidence that hormesis represents an ‘‘overcompensation’’ response to a disruption in homeostasis. Ecotoxicol Environ Safety 1999; 42: 135-137.

48.

Lave LB Hormesis: implications for public policy regarding toxicants. Annu Rev Pub Health 2001; 22: 63-67.

49.

Calabrese EJ , Baldwin LA Hormesis and high-risk groups. Reg Toxicol Pharmacol 2002; 35: 414-428.

50.

Belz RG , Cedergreen N. , Sorensen H.

Hormesis in mixtures - can it be predicted?

Sci Total Environ 2008; 404: 77-87.

51.

Flood JF , Smith GE , Cherkin A. Memory retention - enhancement by cholinergic drug-combinations in mice. Gerontologist 1982; 22: 230-231.

52.

Flood JF , Smith GE , Cherkin A. Memory retention - potentiation of cholinergic drug-combinations in mice. Neurobiol Aging 1983; 4: 37-43.

53.

Flood JF , Smith GE , Cherkin A. Memory retention - enhancement by synergistic oral cholinergic drug-combination in mice. Gerontologist 1984; 24: 149.

54.

Flood JF , Smith GE , Cherkin A. Memory enhancement - supra-additive effect of subcutaneous chlolinergic drug-combinations in mice. Psychopharmacology 1985; 86: 61-67.

55.

Calabrese EJ Converging concepts: adaptive response, preconditioning, and the Yerkes-Dodson law are manifestations of hormesis. Aging Res Rev 2008; 7: 8-20.

56.

Calabrese EJ Hormesis: principles and applications for pharmacology and toxicology. Am J Pharm Toxicol 2008; 3: 56-68.

57.

Murry CE , Jennings RB , Reimer KA Preconditioning with ischemia - a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.

58.

Davies JMS , Lowry CV , Davies KJA. Transcient adaptation to oxidative stressing yeast. Arch Biochem Biophys 1995; 317: 1-6.

59.

Nicolosi AC , Strande JL , Hsu A. , Fu X. , Su J. , Gross GJ , et al. Gadolinium limits myocardial infarction in the rat: dose-response, temporal relations and mechanisms. J Mol Cell Cardiol 2008; 44: 345-351.

60.

National Academy of Sciences (NAS). Toxicity testing in the 21st century - a vision and a strategy. Washington, DC: The National Academies Press, 2007.

61.

Calabrese EJ The future of hormesis. Crit Rev Toxicol 2001; 31: 637-648.

62.

Van Wijk R. , Wiegant FA The similia principle as a therapeutic strategy: a research program on stimulation of self-defense in disordered mammalian cells. Altern Ther Health Med 1997 ; 3: 33-38.

63.

Van Wijk R. , Ovelgonne JH , de Koning E. , Jaarsveld K. , Van Rijn J. , Wiegant FAC. Mild step-down heating causes increased levels of HSP68 and of HSP84 mRNA and enhances thermotolerance . Int J Hyperthermia 1994; 10: 115-125.

64.

Calabrese EJ , et al. Biological stress terminology: integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Tox Appl Pharmacol 2007; 222: 122-128.

65.

Randall WA , Price CW , Welch H. Demonstration of hormesis (increase in fatality rate) by penicillin . Amer J Pub Health 1947; 37: 421-425.

66.

Welch H. , Price CW , Randall WA Increase in fatality rate of E. Typhosa for white mice by streptomycin . J Am Pharm A 1946; 35: 155-158.

67.

Kuratsu J-I. , Kurino M. , Fukunaga K. , Miyamoto E. , Ushio Y. Stimulatory effect of suramin on the proliferation of human glioma cells. Anticancer Res 1995 ; 15: 1263-1268.

68.

Kuratsu J. Commentary. Neurol Med Chir ( Tokyo) 1998; 38: 639.

69.

Rutka J. Commentary. Neurol Med Chir ( Tokyo) 1998; 38: 639.

70.

Tabuchi K. Commentary. Neurol Med Chir ( Tokyo) 1998; 38: 639-640.

71.

Yoshida J. Commentary. Neurol Med Chir ( Tokyo) 1998; 38: 633-640.

72.

Chueh S. -C, Guh J. -H, Chen J. , Lai M. -K, Teng C. -M. Dual effects of ouabain on the regulation of proliferation and apoptosis in human prostatic smooth muscle cells. J Urol 2001; 166: 347-353.

73.

Abramowitz J. , Dai C. , Hirschi KK , Dmitrieva RI , Doris PA , Liu L. , et al. Ouabain- and marinobufagenininduced proliferation of human umbilical vein smooth muscle cells and a rat vascular smooth muscle cells and a rat vascular smooth muscle cell lines, A7r5. Circulation 2003; 108: 3048-3053.

74.

Murrell GAC , Francis MJO , Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990; 265: 659-665.

75.

Bluestein HG , Weisman MH , Zvaifler NJ , Shapiro RF Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome. Lancet 1979; 2: 816-819.

76.

Bramm E. , Binderup L. , Arrigoni-Martelli E. Delayed hypersensitivity to tuberculin in rats: Effects of anti-rheumatic drugs. Acta Pharmacol Toxicol 1979; 44: 75-80.

77.

Nascarella MA , Calabrese EJ The relationship between the IC50, toxic threshold, and the magnitude of stimulatory response in biphasic (hormetic) dose-responses . Reg Toxicol Pharmacol 2009 ; 3: 229-233.

78.

Im HK , Im WB , Von Voigtlander PF , Carter DB , Murray BH , Jacobsen EJ Characterization of U-101017 as a GABAA receptor ligand of dual functionality . Brain Res 1996; 714: 165-168.

79.

Jacobsen EJ , Stelzer LS , TenBrink RE , Belonga KL , Carter DB , Im HK , et al. Piperazine imidazo[1,5-a]-quinoxaline ureas as high-affinity GABA ligands of dual functionality. J Med Chem 1999; 42: 1123-1144.

80.

Jacobsen EJ , TenBrink RE , Stelzer LS , Belonga KL , Carter DB , Im HK , et al. High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the γ-aminobutyric acid A/benzodiazepine receptor complex. J Med Chem 1996; 39: 158-175.

81.

Rattan SIS , Fernandes RA , Demirovic D. , Dymek B. , Lima CF Dose-Response 2008; 7: 90-103.

82.

Calabrese EJ Hormesis and medicine. Br J Clin Pharmacol 2008; 66: 594-617.

83.

Smith Sonneborn J. Hormetic triggers for intervention in aging, disease and trauma. Am J Pharmacol Toxicol 2008; 3: 1-10.

84.

Sagan LA On radiation, paradigms, and hormesis. Science 1989; 245: 574, 621.

85.

Wolff S. Are radiation-induced effects hormetic. Science 1989; 245: 575, 621.

86.

Hoffmann GR A perspective on the scientific, philosophical, and policy dimensions of hormesis. Dose-Response 2009; 7: 1-51.

87.

Scott BR It’s time for a new low-dose-radiation risk assessment paradigm - one that acknowledges hormesis. Dose-Response 2008; 6: 333-351.

88.

Scott BR Low-dose radiation-induced protective process and implications for risk assessment, cancer prevention, and cancer therapy. Dose-Response 2007; 5: 131-149.

89.

Calabrese EJ , Cook RR Hormesis: how it could affect the risk assessment process. Hum Exp Toxicol 2005 ; 24: 265-270.